These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35816278)

  • 1. Paxlovid-Tacrolimus Drug-Drug Interaction in a 23-Year-Old Female Kidney Transplant Patient with COVID-19.
    Berar Yanay N; Bogner I; Saker K; Tannous E
    Clin Drug Investig; 2022 Aug; 42(8):693-695. PubMed ID: 35816278
    [No Abstract]   [Full Text] [Related]  

  • 2. Paxlovid (Nirmatelvir/Ritonavir) and Tacrolimus Drug-Drug Interaction in a Kidney Transplant Patient with SARS-2-CoV infection: A Case Report.
    Prikis M; Cameron A
    Transplant Proc; 2022; 54(6):1557-1560. PubMed ID: 35599203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correspondence on 'Management of nirmatrelvir/ritonavir and tacrolimus interaction in kidney transplant recipients infected by COVID-19: a three-case series'.
    Zhou XX; Ji HJ
    Eur J Hosp Pharm; 2024 Feb; 31(2):178-179. PubMed ID: 36737228
    [No Abstract]   [Full Text] [Related]  

  • 4. Management of nirmatrelvir/ritonavir and tacrolimus interaction in kidney transplant recipients infected by COVID-19: a three-case series.
    Guzmán Cordero C; Saez-Torres de Vicente M
    Eur J Hosp Pharm; 2024 Feb; 31(2):175-177. PubMed ID: 36535689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Special Considerations for Paxlovid Treatment Among Transplant Recipients With SARS-CoV-2 Infection.
    Fishbane S; Hirsch JS; Nair V
    Am J Kidney Dis; 2022 Apr; 79(4):480-482. PubMed ID: 35032591
    [No Abstract]   [Full Text] [Related]  

  • 6. Adaptative Strategy of Immunosuppressive Drugs Dosage Adjustments When Combined With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients With COVID-19.
    Boland L; Devresse A; Monchaud C; Briol S; Belaiche S; Giguet B; Couzi L; Thaunat O; Esposito L; Meszaros M; Roussoulieres A; Haufroid V; Le Meur Y; Lemaitre F
    Transpl Int; 2024; 37():12360. PubMed ID: 38596505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of nirmatrelvir/ritonavir on tacrolimus levels in lung transplant recipients: A single-center study.
    Wang X; Du W; Zhang D; Chen W; Zuo X
    Pulm Pharmacol Ther; 2024 Mar; 84():102280. PubMed ID: 38065402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 update: Prescription of Paxlovid by pharmacists.
    Med Lett Drugs Ther; 2022 Aug; 64(1656):e124. PubMed ID: 35921075
    [No Abstract]   [Full Text] [Related]  

  • 9. Nirmatrelvir/ritonavir treatment of patients with COVID-19 taking tacrolimus: case series describing the results of drug-drug interactions.
    Shen D; Gong Y; Qian Y; Zhu J; Gao J
    J Int Med Res; 2024 May; 52(5):3000605241247705. PubMed ID: 38698526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated tacrolimus levels after treatment with nirmatrelvir/ritonavir (Paxlovid) for COVID-19 infection in a child with a kidney transplant.
    Young C; Papiro T; Greenberg JH
    Pediatr Nephrol; 2023 Apr; 38(4):1387-1388. PubMed ID: 35982345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paxlovid for treatment of COVID-19.
    Med Lett Drugs Ther; 2022 Jan; 64(1642):9-10. PubMed ID: 35134040
    [No Abstract]   [Full Text] [Related]  

  • 12. A case report of drug interaction between co-packaged nirmatrelvir-ritonavir and tacrolimus causing hyponatremia in a lung transplant recipient.
    Lo CM; Chen WH; Tsai MY; Lu HI; Hsiao YH; Chuang KH; Chen Y; Wu HF; Huang KT; Wang YH
    J Cardiothorac Surg; 2024 Mar; 19(1):132. PubMed ID: 38491538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Covid-19: NICE plans to expand Paxlovid eligibility to 1.4 million more people.
    Mahase E
    BMJ; 2024 Jan; 384():q59. PubMed ID: 38212056
    [No Abstract]   [Full Text] [Related]  

  • 14. Covid-19: What is the evidence for the antiviral Paxlovid?
    Extance A
    BMJ; 2022 Apr; 377():o1037. PubMed ID: 35477536
    [No Abstract]   [Full Text] [Related]  

  • 15. The future of Paxlovid for COVID-19.
    Burki T
    Lancet Respir Med; 2022 Jul; 10(7):e68. PubMed ID: 35623373
    [No Abstract]   [Full Text] [Related]  

  • 16. Rapid COVID-19 rebound in a severe COVID-19 patient during 20-day course of Paxlovid.
    Wang Y; Chen X; Xiao W; Zhao D; Feng L
    J Infect; 2022 Nov; 85(5):e134-e136. PubMed ID: 35995309
    [No Abstract]   [Full Text] [Related]  

  • 17. Three more points about Paxlovid for covid-19.
    Phizackerley D
    BMJ; 2022 Jun; 377():o1397. PubMed ID: 35672048
    [No Abstract]   [Full Text] [Related]  

  • 18. Covid-19: FDA authorises pharmacists to prescribe Paxlovid.
    Tanne JH
    BMJ; 2022 Jul; 378():o1695. PubMed ID: 35803606
    [No Abstract]   [Full Text] [Related]  

  • 19. Exploring Paxlovid Efficacy in COVID-19 Patients with MAFLD: Insights from a Single-Center Prospective Cohort Study.
    Buchynskyi M; Oksenych V; Kamyshna I; Kamyshnyi O
    Viruses; 2024 Jan; 16(1):. PubMed ID: 38257811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Paxlovid and Mortality Rates in Critically Ill Patients With COVID-19 Receiving Invasive Mechanical Ventilation: A Retrospective Cohort Study.
    Yang MJ; Jiang L; Xu L; Guo SL
    Chest; 2024 Jan; 165(1):128-131. PubMed ID: 37473858
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.